Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 05.01.2024 · 30 (1) · 20-28
DOI: 10.1093/ibd/izad018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 17.02.2023. Verfasst von Matteo Bramuzzo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. Hauptthemen laut MEDLINE: Thalidomide, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Few drugs have been studied for patients with very early onset inflammatory bowel disease (VEOIBD). This study aimed to evaluate the efficacy and tolerance of thalidomide in children with VEOIBD compared with children with pediatric-onset IBD (pIBD).
Methods
A retrospective cohort study with a control group was conducted. Propensity score 1:1 matching was used to identify control subjects. The treatment persistence; the causes of drug withdrawal; the rate of clinical remission and mucosal healing at 1, 2, and 3 years; and adverse events (AEs) were evaluated in children with VEOIBD treated with thalidomide and compared with children with pIBD.
Results
Thirty-nine courses of treatment with thalidomide in VEOIBD and pIBD patients were compared. The treatment persistence at 1, 2, and 3 years was 68.2% (95% confidence interval [CI], 50.8%-80.6%), 57.0% (95% CI, 39.6%-71.1%), and 50.9% (95% CI, 33.7%-65.8%) for VEOIBD patients and 81.7% (95% CI, 65.3%-90.9%), 60.0% (95% CI, 41.7%-74.3%) and 33.0% (95% CI, 17.4%-49.5%) for pIBD patients, respectively (P = .12). A significantly higher proportion of VEOIBD patients discontinued therapy due to lack of efficacy (48.2% vs 17.2%; P = .03), while AEs were the main reason for discontinuation in pIBD patients. Clinical remission and mucosal healing rates did not significantly differ between VEOIBD and pIBD patients. A significatively lower number of VEOIBD patients experienced AEs compared with pIBD patients (14 [35.9%] vs 30 [76.9%]; P = .0005).
Conclusions
Thalidomide is an effective and tolerated treatment in children with VEOIBD. Discontinuation due to lack of efficacy is more frequent, but AEs are less common than in children with pIBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
- Bureau de biostatistique et d'épidemiologie, Gustave Roussy and Université Paris-Saclay, Paris, France.
- Pediatric Gastroenterology and Endoscopy, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Department NEUROFARBA, Meyer Children's Hospital, University of Florence, Florence, Italy.
- Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood G. Barresi, University of Messina, Messina, Italy.
ORCID-Profile: Matteo Bramuzzo, Paolo Lionetti, Francesco Graziano
Zitieren
APA
Bramuzzo, M., Giudici, F., Arrigo, S., Lionetti, P., Zuin, G., Romano, C., Graziano, F., Faraci, S., Alvisi, P., Signa, S., Scarallo, L., Martelossi, S., & Di Leo, G. (2024). Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 30(1), 20-28. https://doi.org/10.1093/ibd/izad018
Vancouver
Bramuzzo M, Giudici F, Arrigo S, Lionetti P, Zuin G, Romano C, et al. Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2024;30(1):20-28. doi:10.1093/ibd/izad018
BibTeX
@article{Bramuzzo2024,
author = {Bramuzzo, Matteo and Giudici, Fabiola and Arrigo, Serena and Lionetti, Paolo and Zuin, Giovanna and Romano, Claudio and Graziano, Francesco and Faraci, Simona and Alvisi, Patrizia and Signa, Sara and Scarallo, Luca and Martelossi, Stefano and Di Leo, Grazia},
title = {Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2024},
volume = {30},
number = {1},
pages = {20--28},
doi = {10.1093/ibd/izad018}
}
EUVIMED